ADRIATIC buoys Imfinzi’s prospects in early lung cancer

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell lung cancer (SCLC), a less common but aggressive form of the disease.